MALVERN, Pa., Oct. 15 /PRNewswire/ -- Centocor, Inc. (Nasdaq: CNTO) today announced that Jason S. Rubin will join the company October 26, 1998 as vice president, corporate communications, a newly created position. Rubin's areas of responsibility will include investor and media relations, corporate public relations and government affairs.
"We are pleased to welcome such a highly regarded and well-respected executive as Jason Rubin to the Centocor management team," said Dominic J. Caruso, senior vice president and chief financial officer. "We look forward to benefiting from his wealth of industry knowledge and his strong background in corporate communications as Centocor continues to evolve as a major biopharmaceutical company."
Caruso noted that having added two major therapeutic products in 1998 -- Retavase(R) (reteplase) and Remicade(TM) (infliximab) -- to go along with its established product, ReoPro(R) (abciximab), Centocor is looking to strengthen its communication effort given the complex dynamics of today's health care environment. "With nearly 15 years of corporate communications experience for health care companies, Jason is the right individual to help Centocor better address the communications challenges posed by a broad range of constituencies -- investors, media, regulators, legislators and customers," Caruso added.
Rubin, 40, joins Centocor from Cephalon, Inc., a biotechnology firm where he has served since 1993 as vice president, corporate communications, with responsibility for managing the company's investor and media relations, marketing and employee communications, and public affairs activities. Prior to his career at Cephalon, he held senior communications positions with several corporations and public relations agencies, including Immunex Corp., Hill and Knowlton, Inc. and Adams & Rinehart, Inc.
A resident of Villanova, Pa., Rubin earned a B.A. from Middlebury College and an M.S. from the Sloan School of Management at the Massachusetts Institute of Technology. His professional affiliations include the American Association for the Advancement of Science, the Biotechnology Industry Organization, the New York Academy of Sciences, the Pennsylvania Biotechnology Association and the National Investor Relations Institute.
Centocor is a leading biopharmaceutical company that creates, acquires and markets cost-effective therapies that yield long-term benefits for patients and the healthcare community. Its products, developed through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life.
Certain of the matters discussed herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by the Company's management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the Company's filings with the Securities and Exchange Commission that may affect the Company's business and prospects. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.
Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
On the Internet: More company information can be found on Centocor's homepage at www.centocor.com.
No comments:
Post a Comment